Skip to Content

Neurobo Pharmaceuticals, Inc. a clinical-stage biotechnology company focused on developing therapies for liver and metabolic disease with two drugs licensed from our strategic partner and largest shareholder, Dong-A ST Co., Ltd. DA-1241 completed Phase 1 in the US and DA-1726 completed pre-clinical studies.

  • DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist. We plan to initiate a Phase 2a study in 2023.
  • DA-1726 is a novel dual agonist of GLP-1 and glucagon receptors. We are preparing an IND submission for DA-1726 in 2023 to be followed by a Phase 1 Study.
  • Neurobo entered into an exclusive licensing agreement with Dong-A ST Co., Ltd. (KOSE:A000640) to develop and commercialize DA-1241 and DA-1726 on Sept. 15, 2022.